BSE: 507789 | NSE: JAGSNPHARM | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Jagsonpal Pharmaceuticals Ltd is a average quality company.
The key valuation ratios of Jagsonpal Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Jagsonpal Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 4.4% | 3.2% | 5.1% | 3.7% | -9.9% | 7.2% | 7.3% | 14.2% | 14.2% | 18.6% | - |
| Value Creation Index ⓘ | -0.7 | -0.8 | -0.6 | -0.7 | -1.7 | -0.5 | -0.5 | 0.0 | 0.0 | 0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 221 |
| Sales YoY Gr. | - | -4% | 3.9% | 0.3% | -12.1% | 31.9% | -5% | 18.5% | 15.8% | 8.8% | - |
| Adj EPS ⓘ | 0.8 | 0.5 | 1.2 | 1.1 | -4.4 | 2.8 | 3 | 6.5 | 7 | 10.3 | 9.3 |
| YoY Gr. | - | -44.4% | 175.6% | -10.5% | -497.3% | NA | 9.5% | 116.3% | 7.7% | 46.2% | - |
| BVPS (₹) ⓘ | 32.9 | 33.4 | 34.6 | 39 | 34.4 | 36.9 | 39.4 | 43.6 | 50.7 | 57.3 | 67.7 |
| Adj Net Profit ⓘ | 2.1 | 1.2 | 3.3 | 2.9 | -11.6 | 7.2 | 7.9 | 17.1 | 18.4 | 26.8 | 25 |
| Cash Flow from Ops. ⓘ | 7.5 | 4.3 | 9 | -3.2 | -1.6 | 30.9 | 11.9 | 28.2 | 6.9 | 46.7 | - |
| Debt/CF from Ops. ⓘ | 4.8 | 9.2 | 4.3 | -2.5 | -5.3 | 0.1 | 0.5 | 0.2 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.7% | 13.4% | 14.3% | 8.8% | ||||
| Adj EPS ⓘ | 32.6% | NA | 50.5% | 46.2% | ||||
| BVPSⓘ | 6.4% | 10.7% | 13.3% | 13.1% | ||||
| Share Price | 39.3% | 66.3% | 59.6% | -11.7% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.2 | 1.2 | 3.4 | 2.8 | -11.1 | 7.1 | 7.3 | 14.6 | 14.4 | 18.4 | 14.8 |
| Op. Profit Mgn % ⓘ | 7.4 | 6.3 | 8.2 | 4 | -8.8 | 5.6 | 5.4 | 10.2 | 11.7 | 14.6 | 11.7 |
| Net Profit Mgn % ⓘ | 1.5 | 0.9 | 2.3 | 2 | -9.1 | 4.3 | 5 | 9.1 | 8.4 | 11.3 | 11.1 |
| Debt to Equity ⓘ | 0.4 | 0.5 | 0.4 | 0.1 | 0.1 | 0 | 0.1 | 0.1 | 0 | 0 | - |
| Working Cap Days ⓘ | 209 | 226 | 227 | 243 | 277 | 178 | 164 | 130 | 102 | 96 | 138 |
| Cash Conv. Cycle ⓘ | 176 | 186 | 180 | 190 | 209 | 110 | 85 | 55 | 26 | 26 | 115 |
Sales growth is growing at healthy rate in last 3 years 14.29%
Net Profit is growing at healthy rate in last 3 years 50.45%
Return on Equity has declined versus last 3 years average to 14.80%
Sales growth is not so good in last 4 quarters at -4.61%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 9.3 | - |
| TTM Sales (₹ Cr.) | 221 | - |
| BVPS (₹.) ⓘ | 67.7 | - |
| Reserves (₹ Cr.) ⓘ | 166 | - |
| P/BV ⓘ | 4.75 | - |
| PE ⓘ | 34.71 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 270.05 / 513.90 |
| All Time Low / High (₹) | 1.25 / 513.90 |
| Market Cap (₹ Cr.) | 851 |
| Equity (₹ Cr.) | 13.2 |
| Face Value (₹) | 5 |
| Industry PE ⓘ | 47.6 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 |
| Operating Expenses ⓘ | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 193 | 203 |
| Manufacturing Costs | 4 | 3 | 4 | 3 | 2 | 2 | 1 | 1 | 2 | 1 |
| Material Costs | 65 | 69 | 59 | 59 | 61 | 73 | 56 | 81 | 89 | 93 |
| Employee Cost | 38 | 32 | 38 | 41 | 42 | 47 | 50 | 54 | 58 | 65 |
| Other Costs ⓘ | 27 | 26 | 31 | 35 | 33 | 36 | 42 | 33 | 44 | 43 |
| Operating Profit ⓘ | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 25 | 34 |
| Operating Profit Margin (%) | 7.4% | 6.3% | 8.2% | 4.0% | -8.8% | 5.6% | 5.4% | 10.2% | 11.5% | 14.4% |
| Other Income ⓘ | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 4 | 3 | 6 |
| Interest ⓘ | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 |
| Depreciation ⓘ | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | -3 |
| Profit Before Tax ⓘ | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 |
| Tax ⓘ | 0 | 1 | 1 | 3 | 0 | 2 | 2 | 5 | 8 | 8 |
| Profit After Tax | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 |
| PAT Margin (%) | 1.5% | 0.8% | 2.3% | 8.2% | -9.1% | 4.3% | 5.0% | 9.1% | 8.7% | 11.3% |
| Adjusted EPS (₹) | 0.8 | 0.5 | 1.2 | 4.5 | -4.4 | 2.8 | 3.0 | 6.5 | 7.2 | 10.2 |
| Dividend Payout Ratio (%) | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 99 | 95 | 98 | 110 | 98 | 104 | 111 | 122 | 133 | 150 |
| Share Capital ⓘ | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves ⓘ | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 137 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 36 | 39 | 38 | 8 | 8 | 4 | 6 | 7 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 36 | 39 | 38 | 8 | 8 | 4 | 6 | 7 | 0 | 0 |
| Trade Payables | 5 | 8 | 10 | 9 | 9 | 12 | 12 | 18 | 19 | 16 |
| Others Liabilities ⓘ | 17 | 12 | 13 | 16 | 14 | 16 | 20 | 17 | 20 | 36 |
| Total Liabilities ⓘ | 156 | 154 | 159 | 143 | 130 | 136 | 149 | 164 | 171 | 203 |
Fixed Assets | ||||||||||
| Gross Block | 87 | 88 | 90 | 53 | 54 | 55 | 58 | 60 | 58 | 33 |
| Accumulated Depreciation | 31 | 36 | 39 | 31 | 32 | 33 | 34 | 34 | 36 | 12 |
| Net Fixed Assetsⓘ | 56 | 52 | 52 | 22 | 21 | 22 | 24 | 26 | 23 | 21 |
| CWIP ⓘ | 2 | 0 | 0 | 0 | 3 | 4 | 2 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 |
| Inventories | 31 | 33 | 40 | 48 | 51 | 33 | 29 | 30 | 30 | 21 |
| Trade Receivables | 45 | 45 | 42 | 39 | 25 | 21 | 21 | 13 | 16 | 21 |
Cash Equivalents  ⓘ
| 13 | 15 | 16 | 20 | 15 | 39 | 40 | 60 | 25 | 115 |
| Others Assetsⓘ | 9 | 9 | 11 | 14 | 14 | 18 | 20 | 21 | 28 | 24 |
| Total Assets ⓘ | 156 | 154 | 159 | 143 | 130 | 136 | 149 | 164 | 171 | 203 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 8 | 4 | 9 | -3 | -2 | 31 | 12 | 28 | 7 | 47 |
| PBT ⓘ | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 |
| Adjustment ⓘ | 8 | 7 | 8 | -9 | 1 | 0 | -1 | -2 | -1 | 9 |
| Changes in Working Capital ⓘ | -3 | -4 | -2 | -6 | 9 | 20 | 5 | 12 | -11 | 10 |
| Tax Paid ⓘ | -1 | 0 | -1 | -3 | 0 | 2 | -2 | -3 | -7 | -7 |
| Cash Flow From Investing Activity ⓘ | -1 | 0 | -2 | 41 | -3 | -1 | -11 | -2 | -26 | -58 |
| Capex | -1 | -1 | -3 | 41 | -4 | -2 | -2 | 0 | 0 | 1 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | -11 | -4 | -27 | -62 |
| Others ⓘ | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 2 | 3 |
| Cash Flow From Financing Activityⓘ | -4 | -1 | -6 | -34 | -1 | -6 | -2 | -7 | -18 | 0 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7 | 0 |
| Interest Paid ⓘ | -5 | -4 | -5 | -3 | -1 | -1 | -1 | -1 | 0 | 0 |
| Dividend Paid ⓘ | -1 | 0 | 0 | 0 | 0 | -1 | -1 | -3 | -10 | 0 |
| Others ⓘ | 3 | 3 | -1 | -31 | 0 | -5 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 2 | 2 | 1 | 5 | -6 | 24 | -1 | 19 | -36 | -11 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.47 | 1.35 | 3.65 | 12.32 | -12.01 | 7.72 | 7.88 | 15.7 | 15.28 | 18.89 |
| ROCE (%) | 6.57 | 4.93 | 7.32 | 14.26 | -10.52 | 9.8 | 9.46 | 19.43 | 21.23 | 24.15 |
| Asset Turnover Ratio | 0.94 | 0.9 | 0.92 | 0.96 | 0.93 | 1.26 | 1.11 | 1.2 | 1.44 | 1.38 |
| PAT to CFO Conversion(x) | 4 | 4 | 3 | -0.25 | N/A | 4.43 | 1.5 | 1.65 | 0.37 | 1.74 | Working Capital Days |
| Receivable Days | 110 | 118 | 110 | 102 | 93 | 50 | 49 | 33 | 21 | 26 |
| Inventory Days | 76 | 84 | 92 | 110 | 143 | 92 | 71 | 57 | 45 | 36 |
| Payable Days | 20 | 26 | 43 | 49 | 54 | 52 | 77 | 67 | 75 | 68 |
In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.
In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the country’s leading pharmaceutical companies.
In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.
In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpal’s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpal’s current aggressive growth strategy.
Jagsonpal is among India’s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.
The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.
Product range of the company includes:
Upcoming products:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
